ACADEMIA

AZ’s Durvalumab to Become New Treatment Option for Stage III NSCL Cancer: Oncologist

May 28, 2018

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

Nobuyuki Yamamoto, deputy director of the School of Medicine, Wakayama Medical University, expressed his high hopes that AstraZeneca’s PD-L1 inhibitor durvalumab will become a new treatment option for patents with Stage III non-small cell lung cancer (NSCLC). “No noticeable progress…

To read the full story

Oncologist Lauds Imfinzi as Trailblazer in Stage III Lung Cancer, Eagerly Awaiting OS Data
July 24, 2018

ACADEMIA

Japan’s Maternal RSV Vaccine Uptake at 11.6%, Survey Finds
January 15, 2026
Early CGP Testing Cuts Mortality Risk by 41%, Research Shows
December 1, 2025
5-Year Cancer Survival Shows Wide Gap by Tumor Types, Gains Seen in Lymphoma: NCC
November 20, 2025
Japan Sleep Society to Revise Insomnia Guidelines to Reflect Orexin Antagonists
October 8, 2025
Japan’s Sakaguchi Wins 2025 Nobel Prize in Medicine
October 7, 2025

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COLUMN

The Strategic MSL: Beyond Data Delivery, It’s About Impact

By Philip Carrigan

I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…

COMMENTARY

Hisamitsu’s MBO: Is Shareholder Accountability Trust-Building or a Shackle?

By Hayate Horiguchi

Following Hisamitsu Pharmaceutical’s decision to go private through a roughly 400 billion yen management buyout (MBO), industry observers are weighing…